Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.

Shueb SS, Erb SJ, Lunzer MM, Speltz R, Harding-Rose C, Akgün E, Simone DA, Portoghese PS.

Neuropharmacology. 2019 Jul 1:107690. doi: 10.1016/j.neuropharm.2019.107690. [Epub ahead of print]

PMID:
31271770
2.

The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward.

Cataldo G, Erb SJ, Lunzer MM, Luong N, Akgün E, Portoghese PS, Olson JK, Simone DA.

Neuropharmacology. 2019 Nov 1;158:107598. doi: 10.1016/j.neuropharm.2019.04.004. Epub 2019 Apr 7.

PMID:
30970233
3.

Combined Glia Inhibition and Opioid Receptor Agonism Afford Highly Potent Analgesics without Tolerance.

Akgün E, Lunzer MM, Portoghese PS.

ACS Chem Neurosci. 2019 Apr 17;10(4):2004-2011. doi: 10.1021/acschemneuro.8b00323. Epub 2018 Aug 24.

PMID:
30110531
4.

A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance.

Dutta R, Lunzer MM, Auger JL, Akgün E, Portoghese PS, Binstadt BA.

Arthritis Res Ther. 2018 Jul 27;20(1):154. doi: 10.1186/s13075-018-1661-5.

5.

Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.

Cataldo G, Lunzer MM, Olson JK, Akgün E, Belcher JD, Vercellotti GM, Portoghese PS, Simone DA.

Pain. 2018 Jul;159(7):1382-1391. doi: 10.1097/j.pain.0000000000001225.

6.

Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Fleming KA, Ericson MD, Freeman KT, Adank DN, Lunzer MM, Wilber SL, Haskell-Luevano C.

ACS Chem Neurosci. 2018 May 16;9(5):1141-1151. doi: 10.1021/acschemneuro.7b00495. Epub 2018 Feb 13.

7.

Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into Mice.

Adank DN, Lunzer MM, Lensing CJ, Wilber SL, Gancarz AM, Haskell-Luevano C.

ACS Chem Neurosci. 2018 Feb 21;9(2):320-327. doi: 10.1021/acschemneuro.7b00330. Epub 2017 Oct 19.

8.

Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.

Peterson CD, Kitto KF, Akgün E, Lunzer MM, Riedl MS, Vulchanova L, Wilcox GL, Portoghese PS, Fairbanks CA.

Pain. 2017 Dec;158(12):2431-2441. doi: 10.1097/j.pain.0000000000001050.

9.

Heteromer Induction: An Approach to Unique Pharmacology?

Portoghese PS, Akgün E, Lunzer MM.

ACS Chem Neurosci. 2017 Mar 15;8(3):426-428. doi: 10.1021/acschemneuro.7b00002. Epub 2017 Jan 31.

PMID:
28139906
10.

Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).

Akgün E, Javed MI, Lunzer MM, Powers MD, Sham YY, Watanabe Y, Portoghese PS.

J Med Chem. 2015 Nov 12;58(21):8647-57. doi: 10.1021/acs.jmedchem.5b01245. Epub 2015 Oct 20.

11.

Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.

Smeester BA, Lunzer MM, Akgün E, Beitz AJ, Portoghese PS.

Eur J Pharmacol. 2014 Nov 15;743:48-52. doi: 10.1016/j.ejphar.2014.09.008. Epub 2014 Sep 17.

12.

Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.

Le Naour M, Lunzer MM, Powers MD, Kalyuzhny AE, Benneyworth MA, Thomas MJ, Portoghese PS.

J Med Chem. 2014 Aug 14;57(15):6383-92. doi: 10.1021/jm500159d. Epub 2014 Jul 18.

13.

Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception.

Akgün E, Javed MI, Lunzer MM, Smeester BA, Beitz AJ, Portoghese PS.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11595-9. doi: 10.1073/pnas.1305461110. Epub 2013 Jun 24.

14.

Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Le Naour M, Akgün E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE, Portoghese PS.

J Med Chem. 2013 Jul 11;56(13):5505-13. doi: 10.1021/jm4005219. Epub 2013 Jun 20.

15.

Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.

Yekkirala AS, Banks ML, Lunzer MM, Negus SS, Rice KC, Portoghese PS.

ACS Chem Neurosci. 2012 Sep 19;3(9):720-7. Epub 2012 Jul 5.

16.

Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.

Le Naour M, Lunzer MM, Powers MD, Portoghese PS.

J Med Chem. 2012 Jan 26;55(2):670-7. doi: 10.1021/jm200902v. Epub 2012 Jan 5.

17.

N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.

Yekkirala AS, Lunzer MM, McCurdy CR, Powers MD, Kalyuzhny AE, Roerig SC, Portoghese PS.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5098-103. doi: 10.1073/pnas.1016277108. Epub 2011 Mar 8.

18.

A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.

Tang Y, Yang J, Lunzer MM, Powers MD, Portoghese PS.

ACS Med Chem Lett. 2010 Oct 27;2(1):7-10. doi: 10.1021/ml1001294. eCollection 2011 Jan 13.

19.

Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Zheng Y, Akgün E, Harikumar KG, Hopson J, Powers MD, Lunzer MM, Miller LJ, Portoghese PS.

J Med Chem. 2009 Jan 22;52(2):247-58. doi: 10.1021/jm800174p.

20.

Selectivity of delta- and kappa-opioid ligands depends on the route of central administration in mice.

Lunzer MM, Portoghese PS.

J Pharmacol Exp Ther. 2007 Jul;322(1):166-71. Epub 2007 Mar 30.

PMID:
17400888
21.

Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia.

Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6061-5. Epub 2007 Mar 26.

22.

A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.

Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL.

Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9050-5. Epub 2005 Jun 2.

23.

Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord.

Portoghese PS, Lunzer MM.

Eur J Pharmacol. 2003 Apr 25;467(1-3):233-4.

PMID:
12706480
24.

The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care.

Hirsch AT, Halverson SL, Treat-Jacobson D, Hotvedt PS, Lunzer MM, Krook S, Rajala S, Hunninghake DB.

Vasc Med. 2001;6(2):87-96.

PMID:
11530970
25.

Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.

Le Bourdonnec B, El Kouhen R, Lunzer MM, Law PY, Loh HH, Portoghese PS.

J Med Chem. 2000 Jun 29;43(13):2489-92. No abstract available.

PMID:
10891107
26.

Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction.

Hirsch AT, Opsahl JA, Lunzer MM, Katz SA.

Am J Physiol. 1999 Jun;276(6):H1818-26. doi: 10.1152/ajpheart.1999.276.6.H1818.

PMID:
10362659
27.

Temporal induction of clusterin in the peri-infarct zone after experimental myocardial infarction in the rat.

Silkensen JR, Hirsch AT, Lunzer MM, Chmielewski D, Manivel JC, Muellerleile MR, Rosenberg ME.

J Lab Clin Med. 1998 Jan;131(1):28-35.

PMID:
9452124
28.

Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium.

Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT.

Hypertension. 1997 Aug;30(2 Pt 1):259-66.

PMID:
9260990

Supplemental Content

Loading ...
Support Center